Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002032 · ClinicalTrials.gov registry record · NA

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

A NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pharmacia.

Completed
Registry status
NA
Development phase
750
Enrollment target
20
Study locations

NCT00002032: Completed NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, sponsored by Pharmacia.

NCT00002032 is a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection that has completed, run by Pharmacia. The registered enrollment target is 750 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (69% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002032, a NA study of HIV Infections and Mycobacterium Avium-Intracellulare Infection, has completed, sponsored by Pharmacia.

COMPLETED
Registry status
NA
Development phase
750 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary objective is to compare clinical response, quality of life (Karnofsky), and survival between these two groups.

Conditions Studied

HIV Infections Mycobacterium Avium-Intracellulare Infection

Interventions

  • DRUG Rifabutin

Study Locations (20)

New York

  • Brooklyn Veterans Administration - Brooklyn
  • Maimonides Med Ctr - Brooklyn
  • Nassau County Med Ctr - East Meadow
  • Long Island Jewish Med Ctr - New Hyde Park
  • Community Research Initiative - New York

Florida

  • Ctr for Special Immunology - Fort Lauderdale
  • TheraFirst Med Ctrs Inc - Fort Lauderdale
  • Mem Hosp Hollywood - Hollywood
  • VP Med Services / HHCS Research Institute Inc - Orlando

Georgia

  • AIDS Research Consortium of Atlanta - Atlanta
  • Grady Memorial Hosp / Hughs Spalding Med Ctr - Atlanta
  • Dr Winkler Weinberg - Roswell

California

  • Ctr for Special Immunology - Irvine
  • Olive View Med Ctr - Sylmar

Missouri

  • Univ of Missouri at Kansas City School of Medicine - Kansas City
  • Research Med Ctr - Kansas City

Colorado

  • Denver Public Health Dept - Denver

District of Columbia

  • Veterans Administration Med Ctr - Washington D.C.

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Trial Details

FieldValue
Enrollment Target 750 participants
Phase NA
Pharmacia

7 total trials

What the finished NCT00002032 record still lists

NCT00002032 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (69% higher).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Rifabutin is the first listed.

NCT00002032 names 20 study sites across 9 states, led by New York, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00002032 about?

NCT00002032 is a clinical study titled "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial". The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary o...

What is the current status of trial NCT00002032?

This trial is currently completed. It is a NA study. The enrollment target is 750 participants.

What conditions does trial NCT00002032 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection.

What interventions are being tested in trial NCT00002032?

The interventions under investigation include: Rifabutin (DRUG).

Who is sponsoring clinical trial NCT00002032?

This trial is sponsored by Pharmacia, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002032 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002032's enrollment target sits among peer trials

750 41st of 542 higher than 501 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02048332 · 750 participants · Phase 1

    Donor-Derived Viral Specific T-cells (VSTs)

  • NCT02087852 · 750 participants

    Kidney Cancer DNA Registry

  • NCT02532452 · 750 participants · Phase 2

    Third Party Viral Specific T-cells (VSTs)

  • NCT03126916 · 750 participants · Phase 3

    Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Related registry views

Source: ClinicalTrials.gov NCT00002032, the US trial registry maintained by the National Library of Medicine. NCT00002032 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.